ClinicalTrials.gg
Active, not recruitingNCT06712563CHOROSUpdated Jul 22, 2026

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

An observational study in Pulmonary Disease, Chronic Obstructive, sponsored by AstraZeneca. Active, not recruiting at 7 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by AstraZeneca · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Planned enrollment
32nd of 89
2,000 · median 976
Started
2025
with 12 others
Observational
90 of 284
7 open now
Primary completion
2026-12
later than 1 of 14 live
Registered
266th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 32nd largest by planned enrollment of the 89 observational ones that give a count, is one of 13 that started in 2025, is one of 90 observational ones, reaches primary completion later than 1 of the 14 other live ones, and was the 266th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

The CHOROS pooled analysis is a retrospective secondary data use analysis of integrated individual participant data from a series of planned and on-going primary prospective, non-interventional, multi-center studies sponsored by AstraZeneca and conducted in the pulmonary/primary care practitioner setting in multiple countries and may include data from the following countries: United Kingdom, Germany, Italy, Greece, Japan, Canada and Romania.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with COPD who are new initiators of BGF enrolled in several planned and on-going prospective, non-interventional single-arm studies. Eligible patients for the individual studies are those with moderate to severe COPD and initiating BGF treatment according to the local prescribing guidance and as per their treating physician's recommendation. Only patients that have signed an informed consent form (ICF) allowing the secondary use of their data will be eligible for the CHOROS pooled analysis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with moderate to severe and initiating BGF treatment according to the local prescribing guidance and as per their treating physician's recommendation
  • Enrolled in on-going single-arm studies
  • Provided consent for secondary use of data

Exclusion criteria

Exclusion Criteria:

  • Did not provide consent for secondary use of data
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • BGF Initiators

    New initiators of BGF without prior BGF exposure

    Drug: Budesonide/glycopyrrolate/formoterol fumarate

Interventions

  • DrugBudesonide/glycopyrrolate/formoterol fumarate

    Drug pages: BudesonideStudies of BudesonideBudesonide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · GlycopyrrolateStudies of GlycopyrrolateGlycopyrrolate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · FormoterolStudies of FormoterolFormoterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Budesonide/glycopyrrolate/formoterol fumarate (BGF) is a triple fixed-dose combination therapy for adults with moderate to severe COPD who are not adequately treated by a combination of inhaled corticosteroids and long-acting beta-agonist (LABA), or LABA and long-acting muscarinic-antagonist

    Also known as: BGF, Breztri

06

What researchers measure

Primary outcomes

  1. COPD Assessment Test (CAT)

    Compare self-reported COPD health status measured by COPD Assessment Test (CAT) at 12 weeks/3 months as compared to baseline in patients initiating treatment with BGF

    Time frame: 12 weeks

Secondary outcomes

  1. COPD Assessment Test

    To compare self-reported COPD health status measured by CAT at 4 weeks/1 month as compared to baseline in patients initiating treatment with BGF

    Time frame: 4 weeks

  2. COPD Assessment Test

    To compare self-reported COPD health status measured by CAT at 52 weeks/12 months as compared to baseline in patients initiating treatment with BGF

    Time frame: 52 weeks

  3. COPD Assessment Test Responder Rate

    To describe the frequency and proportion of responders of the CAT questionnaire after 12 weeks/3 months of initiating treatment with BGF

    Time frame: 12 weeks

  4. Treatment Satisfaction Questionnaire for Medication (TSQM)

    To evaluate treatment satisfaction using Treatment Satisfaction Questionnaire for Medication (TSQM) after 12 weeks/3months and 52 weeks/12 months of initiating treatment with BGF

    Time frame: 12 weeks and 52 weeks

  5. Annual rate of COPD exacerbations

    To compare the annual rates of moderate and severe exacerbations for the follow-up period (up to 52 weeks/12 months) versus the baseline period (12 months prior to initiating BGF)

    Time frame: 52 weeks

07

Study locations

7 sites
  • Research Site
    Mississauga, Canada
  • Research Site
    Hamburg, Germany
  • Research Site
    Athens, Greece
  • Research Site
    Milan, Italy
  • Research Site
    Tokyo, Japan
  • Research Site
    Bucharest, Romania
  • Research Site
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 2, 2024
StartActual
Apr 17, 2025
Primary completionEst.
Dec 14, 2026
CompletionEst.
Dec 14, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06712563
Lead sponsor
AstraZeneca
Collaborators
IQVIA Pty Ltd
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Apr 17, 2025
Primary completion
Dec 14, 2026 (estimated)
Completion
Dec 14, 2026 (estimated)
Last update
Jul 22, 2026

Study contacts

Michael F Pollack, MS
principal investigator · AstraZeneca

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion